Phase II Study Open, Not Randomized to Evaluate the Efficacy and Safety of Neoadjuvant Treatment With Gemcitabine and Erlotinib Followed by Gemcitabine, Erlotinib and Radiotherapy in Patients With Resectable Pancreatic Adenocarcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 23 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
- 23 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017.
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.